Integre Asset Management LLC continued to hold its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 11,593 shares of the biopharmaceutical company’s stock at the end of the fourth quarter. Integre Asset Management LLC’s holdings in Gilead Sciences were worth $830,000 as of its most recent SEC filing.
Several other institutional investors also recently modified their holdings of GILD. State Street Corp boosted its stake in Gilead Sciences by 4.5% in the fourth quarter. State Street Corp now owns 60,448,831 shares of the biopharmaceutical company’s stock worth $4,328,739,000 after buying an additional 2,587,072 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Gilead Sciences by 0.6% in the third quarter. Bank of New York Mellon Corp now owns 26,786,930 shares of the biopharmaceutical company’s stock worth $2,119,382,000 after buying an additional 169,701 shares in the last quarter. BlackRock Fund Advisors boosted its stake in Gilead Sciences by 6.8% in the third quarter. BlackRock Fund Advisors now owns 26,032,555 shares of the biopharmaceutical company’s stock worth $2,059,696,000 after buying an additional 1,663,268 shares in the last quarter. Parnassus Investments CA boosted its stake in Gilead Sciences by 27.5% in the third quarter. Parnassus Investments CA now owns 10,790,358 shares of the biopharmaceutical company’s stock worth $853,733,000 after buying an additional 2,329,874 shares in the last quarter. Finally, Boston Partners boosted its stake in Gilead Sciences by 51.7% in the third quarter. Boston Partners now owns 9,855,682 shares of the biopharmaceutical company’s stock worth $779,781,000 after buying an additional 3,358,289 shares in the last quarter. 74.19% of the stock is owned by institutional investors and hedge funds.
Gilead Sciences, Inc. (NASDAQ:GILD) traded down 0.86% during mid-day trading on Friday, reaching $65.93. The company had a trading volume of 7,241,809 shares. The firm has a market capitalization of $86.17 billion, a price-to-earnings ratio of 6.63 and a beta of 1.11. Gilead Sciences, Inc. has a 12-month low of $65.38 and a 12-month high of $103.10. The firm has a 50-day moving average price of $67.57 and a 200 day moving average price of $71.70.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 30th. Stockholders of record on Thursday, March 16th were paid a $0.52 dividend. The ex-dividend date was Tuesday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.47. This represents a $2.08 dividend on an annualized basis and a dividend yield of 3.15%. Gilead Sciences’s dividend payout ratio is 18.91%.
Several research firms have weighed in on GILD. Piper Jaffray Companies reiterated an “overweight” rating on shares of Gilead Sciences in a report on Thursday, February 16th. BMO Capital Markets reissued a “market perform” rating and issued a $88.00 price target on shares of Gilead Sciences in a research note on Friday, January 13th. Cowen and Company reissued a “buy” rating and issued a $100.00 price target on shares of Gilead Sciences in a research note on Monday, April 17th. Maxim Group reissued a “hold” rating on shares of Gilead Sciences in a research note on Friday. Finally, Zacks Investment Research raised Gilead Sciences from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 11th. Eleven investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and two have assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $83.86.
In related news, EVP Gregg H. Alton sold 5,000 shares of the company’s stock in a transaction on Thursday, March 30th. The shares were sold at an average price of $67.48, for a total transaction of $337,400.00. Following the completion of the transaction, the executive vice president now owns 117,988 shares in the company, valued at $7,961,830.24. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction on Monday, April 3rd. The stock was sold at an average price of $67.18, for a total transaction of $4,926,510.94. Following the transaction, the insider now owns 3,199,969 shares of the company’s stock, valued at approximately $214,973,917.42. The disclosure for this sale can be found here. Corporate insiders own 1.40% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
